Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance

References

• Jahangir MA, Imam SS, Kazmi I, et al. Type 2 diabetes current and future medications: a short review. Int J Pharm Pharmacol. 2017;1:101.
   Google Scholar
• Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876–886.
   PubMed Web of Science ®Google Scholar
• Harsha S, Attimard M, Khan TA, et al. Design and formulation of mucoadhesive microspheres of sitagliptin. J Microencapsul. 2013;30:257–264.
   PubMed Web of Science ®Google Scholar
• Prasanthi S, Prasad AR, Kumar YG, et al. Formulation and evaluation of sitagliptin phosphate and simvastatin bilayered tablets. Indo Am J Pharm Res. 2015;5:2231–6876.
   Google Scholar
• Maringanti PS, Nalagonda C. Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets. Int J Drug Deliv. 2013;5:15.
   Google Scholar
• Keerthi K, Kothamasu A, Makineni SN, et al. Formulation and evaluation of sitagliptin phosphate gastro retentive tablets. Carib J Sci Tech. 2014;2:270–281.
   Google Scholar
• Patil GB, Patil ND, Deshmukh PK, et al. Nanostructured lipid carriers as a potential vehicle for Carvedilol delivery: application of factorial design approach. Artif Cells Nanomed Biotechnol. 2016;44:12–19.
   PubMed Web of Science ®Google Scholar
• Cetin M, Atila A, Sahin S, et al. Preparation and characterization of metformin hydrochloride loaded-Eudragit® RSPO and Eudragit® RSPO/PLGA nanoparticles. Pharm Dev Technol. 2013;18:570–576.
   PubMed Web of Science ®Google Scholar
• Jafari-Aghdam N, Adibkia K, Payab S, et al. Methylprednisolone acetate–Eudragit® RS100 electrospuns: preparation and physicochemical characterization. Artif Cells Nanomed Biotechnol. 2016;44:497–503.
   PubMed Web of Science ®Google Scholar
• Garjani A, Barzegar-Jalali M, Osouli-Bostanabad K, et al. Morphological and physicochemical evaluation of the propranolol HCl–Eudragit® RS100 electrosprayed nanoformulations. Artif Cells Nanomed Biotechnol. 2017 [Jun 6];[8 p.]. DOI:https://doi.org/10.1080/21691401.2017.1337027
   Google Scholar
• Younis N, Shaheen MA, Abdallah MH. Silymarin-loaded Eudragit® RS100 nanoparticles improved the ability of silymarin to resolve hepatic fibrosis in bile duct ligated rats. Biomed Pharmacother. 2016;31:93–103.
   Web of Science ®Google Scholar
• Elshafeey AH, Kamel AO, Awad GA. Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. Colloids Surf B Biointerfaces. 2010;75:398–404.
   PubMed Web of Science ®Google Scholar
• Kumar N, Chaurasia S, Patel RR, et al. Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile. Pharm Dev Technol. 2017;22:156–167.
   PubMed Web of Science ®Google Scholar
• Wadher KJ, Nagarkar A, Sahare D, et al. Formulation and evaluation of sustained release ciprofloxacin hydrocloride microspheres using synthetic polymers. Int J Pharm Tech Res. 2013;5:773–780.
   Google Scholar
• Hasan AA, Sabry SA, Abdallah MH, et al. Formulation and in vitro characterization of poly(dl-lactide-co-glycolide)/Eudragit RLPO or RS30D nanoparticles as an oral carrier of levofloxacin hemihydrate. Pharm Dev Technol. 2016;21:655–663.
   PubMed Web of Science ®Google Scholar
• Yadav SK, Mishra S, Mishra B. Eudragit-based nanosuspension of poorly water-soluble drug: formulation and in vitro-in vivo evaluation. AAPS PharmSciTech. 2012;13:1031–1044.
   PubMed Web of Science ®Google Scholar
• Gandhi A, Jana S, Sen KK. In-vitro release of acyclovir loaded Eudragit RLPO(®) nanoparticles for sustained drug delivery. Int J Biol Macromol. 2014;67:478–482.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wu X, Meng L, et al. Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int J of Pharm. 2012;436:341–350.
   PubMed Web of Science ®Google Scholar
• Malakar J, Sen SO, Nayak AK, et al. Formulation, optimization and evaluation of transferosomal gel for transdermal insulin delivery. Saudi Pharm J. 2012;20:355–363.
   PubMed Web of Science ®Google Scholar
• Singh B, Kumar R, Ahuja N. Optimizing drug delivery systems using systematic ‘‘design of experiments.’’ Part I: fundamental aspects. Crit Rev Ther Drug Carrier Syst. 2005a;22:27–105.
   PubMed Web of Science ®Google Scholar
• Jamal M, Imam SS, Aqil M, et al. Transdermal potential and anti-arthritic efficacy of ursolic acid from niosomal gel systems. Int Immunopharmacol. 2015;29:361–369.
   PubMed Web of Science ®Google Scholar
• Qumbar M, Ameeduzzafar Imam SS, et al. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: in-vitro characterization and in-vivo activity. Biomed Pharmacother. 2017;93:255–266.
   PubMed Web of Science ®Google Scholar
• Qadri GR, Ahad A, Aqil M, et al. Invasomes of isradipine for enhanced transdermal delivery against hypertension: formulation, characterization, and in vivo pharmacodynamic study. Artif Cells Nanomed Biotechnol. 2017;45:139–145.
   PubMed Web of Science ®Google Scholar
• Prasad PS, Imam SS, Aqil M, et al. QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes. Drug Deliv. 2016;23:1047–1056.
   PubMed Web of Science ®Google Scholar
• Alam S, Aslam M, Khan A, et al. Nanostructured lipid carriers of pioglitazone for transdermal application: from experimental design to bioactivity detail. Drug Deliv. 2016;23:601–609.
   PubMed Web of Science ®Google Scholar
• Khan A, Imam SS, Aqil M, et al. Brain targeting of temozolomide via the intranasal route using lipid-based nanoparticles: brain pharmacokinetic and scintigraphic analyses. Mol Pharm. 2016;13:3773–3782.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Imam SS, Ameeduzzafar, et al. In vitro and preclinical assessment of factorial design based nanoethosomes transgel formulation of an opioid analgesic. Artif Cells Nanomed Biotechnol. 2016;44:1793–1802.
   PubMed Web of Science ®Google Scholar
• Imam SS, Aqil M, Ahad A, et al. Formulation by design-based proniosome for accentuated transdermal delivery of risperidone: in vitro characterization and in vivo pharmacokinetic study. Drug Deliv. 2015;22:1059–1070.
   PubMed Web of Science ®Google Scholar
• Reis CP, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine. 2006;2:8–21.
   PubMed Web of Science ®Google Scholar
• Imam SS, Aqil M, Ahad A, et al. Formulation by design based risperidone nano soft lipid vesicle as a new strategy for enhanced transdermal drug delivery: in-vitro characterization, and in-vivo appraisal. Mater Sci Eng C Mater Biol Appl. 2017;75:1198–1205.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Gull A, Alam M, et al. Ultrasonically tailored, chemically engineered and “QbD” enabled fabrication of agomelatine nanoemulsion; optimization, characterization, ex-vivo permeation and stability study. Ultrason Sonochem. 2018;41:213–226.
   PubMed Web of Science ®Google Scholar
• Zhiwen Z, Huihui B, Zhiwei G, et al. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats. Int J Pharm. 2010;394:147–153.
   PubMed Web of Science ®Google Scholar
• Costa P, Lobo JMS. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001; 13:123–133.
   PubMed Web of Science ®Google Scholar
• Paudel A, Ameeduzzafar Imam SS, Fazil M, et al. Formulation and optimization of Candesartan Cilexetil nano lipid carrier: in-vitro and In-vivo evaluation. Current Drug Deliv. 2017; 14:1005–1015.
   PubMed Web of Science ®Google Scholar
• Rezk MR, Riad SM, Mahmoud GY, et al. Simultaneous determination of sitagliptin and metformin in their pharmaceutical formulation. J AOAC Int. 2013;96:301–306.
   PubMed Web of Science ®Google Scholar
• Arora S, Ojha SK, Vohora D. Characterisation of Streptozotocin induced diabetes mellitus in Swiss albino mice. Glob J Pharm. 2009;3:81–84.
   Google Scholar
• Moghddam SMM, Ahad A, Aqil M, et al. Optimization of nanostructured lipid carriers for topical delivery of nimesulide using Box–Behnken design approach. Artif Cells Nanomed Biotechnol. 2017;45:617–624.
   PubMed Web of Science ®Google Scholar
• Mallamma T, Bharathi DR, Lakshmi RG, et al. Etoposide-loaded nanoparticles made from poly-e-caprolactone (PCL): formulation characterization, in vitro drug release for controlled drug delivery system. Int J Biopharm. 2014;5:5–12.
   Google Scholar
• Abdallah MH. Box-behnken design for development and optimization of acetazolamide microspheres. Int J Pharm Sci Res. 2014;5:1228–1239.
   Google Scholar
• Nandy BC, Mazumder B. Formulation and characterizations of delayed release multi particulates system of indomethacin: optimization by response surface methodology. Curr Drug Deliv. 2014;11:72–86.
   PubMed Web of Science ®Google Scholar
• Ahmad N, Amin S, Neupane YR, Kohli K. Anal fissure nanocarrier of lercanidipine for enhanced transdermal delivery: formulation optimization, ex vivo and in vivo assessment. Expert Opin Drug Deliv. 2014;11:467–478.
   PubMed Web of Science ®Google Scholar